Jpmorgan Chase & CO Pro Qr Therapeutics N.V. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PRQR
# of Institutions
52Shares Held
17.4MCall Options Held
37.7KPut Options Held
21.3K-
Privium Fund Management B.V.5.63MShares$15.7 Million2.56% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.63MShares$10.1 Million0.01% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA1.84MShares$5.12 Million0.14% of portfolio
-
M28 Capital Management LP Stamford, CT1.02MShares$2.84 Million1.76% of portfolio
-
Dafna Capital Management LLC Los Angeles, CA906KShares$2.53 Million0.42% of portfolio
About ProQR Therapeutics N.V.
- Ticker PRQR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,362,096
- Market Cap $199M
- Description
- ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...